​

Krystal Biotech (KRYS) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

KRYS Stock Forecast

Krystal Biotech (KRYS) stock forecast, based on 17 Wall Street analysts, predicts a 12-month average price target of $395.20, with a high of $474.00 and a low of $300.00. This represents a 23.45% increase from the last price of $320.13.

$150 $220 $290 $360 $430 $500 High: $474 Avg: $395.2 Low: $300 Last Closed Price: $320.13

KRYS Stock Rating

Krystal Biotech stock's rating consensus is Buy, based on 17 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 17 Buy (100.00%), 0 Hold (0.00%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 17 0 17 Strong Sell Sell Hold Buy Strong Buy

KRYS Price Target Upside V Benchmarks

TypeNameUpside
StockKrystal Biotech23.45%
SectorHealthcare Stocks 15.45%
IndustryBiotech Stocks 41.48%

Price Target Trends

1M3M12M
# Anlaysts129
Avg Price Target$441.00$420.50$367.44
Last Closing Price$320.13$320.13$320.13
Upside/Downside37.76%31.35%14.78%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Oct, 261101--12
Sep, 26191--11
Aug, 26-91--10
Jul, 26-101--11
Jun, 26-101--11
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Sep 24, 2026Andrea NewkirkGoldman Sachs$441.00$341.7529.04%37.76%
Aug 14, 2026Lisa WalterRBC Capital$400.00$328.3421.82%24.95%
Jul 13, 2026Jefferies$474.00$358.5232.21%48.06%
Jun 16, 2026Joseph PantginisH.C. Wainwright$361.00$323.0011.76%12.77%
May 05, 2026Evercore ISI$300.00$294.072.02%-6.29%
Feb 18, 2026Geulah LivshitsChardan Capital$323.00$282.6514.28%0.90%
Feb 17, 2026Roger SongJefferies$371.00$291.1027.45%15.89%
Jan 30, 2026Goldman Sachs$327.00$279.3417.06%2.15%
Jan 09, 2026H.C. Wainwright$310.00$248.9124.54%-3.16%
Oct 17, 2025Debjit ChattopadhyayGuggenheim$224.00$188.3318.94%-30.03%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Oct 15, 2026CitigroupBuyBuyhold
Aug 14, 2026RBC CapitalOutperforminitialise
Aug 04, 2026CitigroupBuyBuyhold
Jul 13, 2026JefferiesBuyBuyhold
Jun 18, 2026Cowen & Co.BuyBuyhold
Jun 16, 2026H.C. WainwrightBuyBuyhold
May 05, 2026Evercore ISIOutperformOutperformhold
May 05, 2026CitigroupBuyBuyhold
Mar 26, 2026Wolfe ResearchPeer Performinitialise
Feb 18, 2026CitigroupBuyBuyhold

Financial Forecast

EPS Forecast

$-5 $1 $7 $13 $19 $25 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$0.40$3.12$7.08---
Avg Forecast$-0.12$2.87$6.02$8.86$12.58$18.94
High Forecast$0.02$3.70$7.86$14.60$21.71$21.09
Low Forecast$-0.30$2.00$3.35$4.61$8.67$16.09
Surprise %-433.33%8.71%17.61%---

Revenue Forecast

$0 $300M $600M $900M $1B $2B Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$50.70M$290.51M$389.13M---
Avg Forecast$36.32M$291.49M$486.01M$709.09M$919.70M$1.26B
High Forecast$52.23M$295.81M$508.48M$729.99M$941.47M$1.37B
Low Forecast$24.67M$288.73M$451.36M$688.20M$897.93M$1.11B
Surprise %39.57%-0.33%-19.93%---

Net Income Forecast

$-50M $90M $230M $370M $510M $650M Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$10.93M$89.16M$204.83M---
Avg Forecast$-3.81M$79.02M$187.05M$320.43M$416.67M$525.62M
High Forecast$613.46K$102.56M$218.25M$405.05M$602.51M$585.29M
Low Forecast$-8.24M$55.47M$93.05M$128.06M$240.71M$446.55M
Surprise %-386.76%12.84%9.51%---

KRYS Forecast FAQ

Is Krystal Biotech stock a buy?

Krystal Biotech stock has a consensus rating of Buy, based on 17 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 17 Buy, 0 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Krystal Biotech is a favorable investment for most analysts.

What is Krystal Biotech's price target?

Krystal Biotech's price target, set by 17 Wall Street analysts, averages $395.2 over the next 12 months. The price target range spans from $300 at the low end to $474 at the high end, suggesting a potential 23.45% change from the previous closing price of $320.13.

How does Krystal Biotech stock forecast compare to its benchmarks?

Krystal Biotech's stock forecast shows a 23.45% upside, outperforming the average forecast for the healthcare stocks sector (15.45%) and underperforming the biotech stocks industry (41.48%).

What is the breakdown of analyst ratings for Krystal Biotech over the past three months?

  • October 2026: 8.33% Strong Buy, 83.33% Buy, 8.33% Hold, 0% Sell, 0% Strong Sell.
  • September 2026: 9.09% Strong Buy, 81.82% Buy, 9.09% Hold, 0% Sell, 0% Strong Sell.
  • August 2026: 0% Strong Buy, 90.00% Buy, 10.00% Hold, 0% Sell, 0% Strong Sell.

What is Krystal Biotech’s EPS forecast?

Krystal Biotech's average annual EPS forecast for its fiscal year ending in December 2026 is $8.86, marking a 25.14% increase from the reported $7.08 in 2025. Estimates for the following years are $12.58 in 2027, and $18.94 in 2028.

What is Krystal Biotech’s revenue forecast?

Krystal Biotech's average annual revenue forecast for its fiscal year ending in December 2026 is $709.09M, reflecting a 82.22% increase from the reported $389.13M in 2025. The forecast for 2027 is $919.7M, and $1.26B for 2028.

What is Krystal Biotech’s net income forecast?

Krystal Biotech's net income forecast for the fiscal year ending in December 2026 stands at $320.43M, representing an 56.44% increase from the reported $204.83M in 2025. Projections indicate $416.67M in 2027, and $525.62M in 2028.